Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.03.22.22272769: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval: This project received approval from the Institutional Review Board of the University of Hong Kong. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We found no effect of two doses of CoronaVac and a limited effect of BNT162b2 against mild/moderate disease, with the caveat that many individuals …
SciScore for 10.1101/2022.03.22.22272769: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval: This project received approval from the Institutional Review Board of the University of Hong Kong. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We found no effect of two doses of CoronaVac and a limited effect of BNT162b2 against mild/moderate disease, with the caveat that many individuals had received their second dose several months before exposure to the SARS-CoV-2 virus. Limited protection against mild/moderate disease was restored with third doses for both vaccines, but we were only able to estimate VE for the short period since administration of third vaccine doses, and it is unclear how long this protection will last. Although improved effectiveness of a third dose was observed against severe outcomes in younger age groups, the absolute VE of two doses remains high in this age group for both vaccines and the relative effects should be interpreted accordingly.29 Our finding that three doses of CoronaVac are needed for older adults to achieve high levels of protection is consistent with World Health Organization recommendations for this group.30 While there is a preferential recommendation in Hong Kong for a third dose of BNT162b2 in adults who received two doses of CoronaVac,31 this did not translate to preference in the community. Of all adults who had received two doses of CoronaVac and a third dose, only 26% received the third dose with BNT162b2. We were unable to evaluate the comparative effectiveness of heterologous vs homologous third dose schedules or durability of three dose protection in this study, but evidence from our analyses that three doses of inactivated vaccine provides a high level of protecti...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-